Patents by Inventor Krishnan Raman

Krishnan Raman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyrrolopyrimidine amines as complement inhibitors
    Patent number: 12679843
    Abstract: Disclosed are compounds of formula (I), and pharmaceutically acceptable salts thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.
    Type: Grant
    Filed: April 2, 2021
    Date of Patent: July 14, 2026
    Assignee: BioCryst Pharmaceuticals, Inc.
    Inventors: Pravin L. Kotian, Yarlagadda S. Babu, Minwan Wu, Zhao Dang, Trung Xuan Nguyen, Krishnan Raman
  • ORAL COMPLEMENT FACTOR D INHIBITORS
    Publication number: 20260165999
    Abstract: Disclosed are compounds of formula (I), and pharmaceutically acceptable salts thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.
    Type: Application
    Filed: December 30, 2025
    Publication date: June 18, 2026
    Inventors: Pravin L. Kotian, Yarlagadda S. Babu, Weihe Zhang, Peng-Cheng Lu, Andrew E. Spaulding, Wei Lv, Zhao Dang, Krishnan Raman
  • SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS
    Publication number: 20260092045
    Abstract: Disclosed are compounds of formulae I and II, and pharmaceutically acceptable salts and prodrugs thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.
    Type: Application
    Filed: December 8, 2025
    Publication date: April 2, 2026
    Inventors: Pravin L. Kotian, Yarlagadda S. Babu, Weihe Zhang, Peng-Cheng Lu, Minwan Wu, Wei Lv, Trung Xuan Nguyen, Zhao Dang, Venkat R. Chintareddy, V. Satish Kumar, Krishnan Raman
  • Oral complement factor D inhibitors
    Patent number: 12558341
    Abstract: Disclosed are compounds of formula (I), and pharmaceutically acceptable salts thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.
    Type: Grant
    Filed: October 9, 2020
    Date of Patent: February 24, 2026
    Assignee: BioCryst Pharmaceuticals, Inc.
    Inventors: Pravin L. Kotian, Yarlagadda S. Babu, Weihe Zhang, Peng-Cheng Lu, Andrew E. Spaulding, Wei Lv, Zhao Dang, Krishnan Raman
  • Pyrrolo 12.3-dipyrimidine compounds and analogues thereof
    Patent number: 12485109
    Abstract: Disclosed are compounds of formula I, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising a compound of formula I, and methods involving use of the compounds and compositions in the treatment and prevention of diseases and conditions characterized by aberrant complement system activity.
    Type: Grant
    Filed: January 23, 2023
    Date of Patent: December 2, 2025
    Assignee: BioCryst Pharmaceuticals, Inc.
    Inventors: Pravin L. Kotian, Yarlagadda S. Babu, Weihe Zhang, Lakshminarayana Vogeti, Minwan Wu, Venkat R. Chintareddy, Krishnan Raman
  • ORAL COMPLEMENT FACTOR D INHIBITORS
    Publication number: 20250275991
    Abstract: Disclosed are compounds of formula (I)-(IV), and pharmaceutically acceptable salts thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.
    Type: Application
    Filed: October 9, 2020
    Publication date: September 4, 2025
    Inventors: Pravin L. Kotian, Yarlagadda S. Babu, Weihe Zhang, Peng-Cheng LU, Andrew E. Spaulding, Minwan Wu, Wei Lv, Trung Xuan Nguyen, Zhao Dang, Krishnan Raman
  • ORAL COMPLEMENT FACTOR D INHIBITORS
    Publication number: 20250186391
    Abstract: Disclosed are compounds of formula (I), and pharmaceutically acceptable salts thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.
    Type: Application
    Filed: October 9, 2020
    Publication date: June 12, 2025
    Inventors: Pravin L. Kotian, Yarlagadda S. Babu, Weihe Zhang, Peng-Cheng Lu, Andrew E. Spaulding, Wei Lv, Zhao Dang, Krishnan Raman
  • IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE
    Publication number: 20240376117
    Abstract: Disclosed are compounds of formula I, II, III, and IV, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of ALK2 kinase. Also provided are pharmaceutical compositions comprising a compound of formula I, II, III, or IV, or pharmaceutically acceptable salt thereof, and methods involving use of the compounds or pharmaceutically acceptable salts thereof and compositions in the treatment and prevention of various diseases and conditions, such as fibrodysplasia ossificans progressiva.
    Type: Application
    Filed: April 26, 2024
    Publication date: November 14, 2024
    Inventors: Pravin L. Kotian, Yarlagadda S. Babu, V. Satisha Kumar, Weihe Zhang, Peng-Cheng Lu, Krishnan Raman
  • SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS
    Publication number: 20240294494
    Abstract: Disclosed are compounds of formulae I and II, and pharmaceutically acceptable salts and prodrugs thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.
    Type: Application
    Filed: January 8, 2024
    Publication date: September 5, 2024
    Inventors: Pravin L. Kotian, Yarlagadda S. Babu, Weihe Zhang, Peng-Cheng Lu, Minwan Wu, Wei Lv, Trung Xuan Nguyen, Zhao Dang, Venkat R. Chintareddy, V. Satish Kumar, Krishnan Raman
  • IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE
    Publication number: 20240270750
    Abstract: Disclosed are compounds of formula I, II, III, and IV, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of ALK2 kinase. Also provided are pharmaceutical compositions comprising a compound of formula I, II, III, or IV, or pharmaceutically acceptable salt thereof, and methods involving use of the compounds or pharmaceutically acceptable salts thereof and compositions in the treatment and prevention of various diseases and conditions, such as fibrodysplasia ossificans progressiva.
    Type: Application
    Filed: May 24, 2022
    Publication date: August 15, 2024
    Inventors: Pravin L. Kotian, Yarlagadda S. Babu, Weihe Zhang, Wei Lv, Peng-Cheng Lu, Andrew E. Spaulding, Krishnan Raman
  • Imidazole-containing inhibitors of ALK2 kinase
    Patent number: 12054492
    Abstract: Disclosed are compounds of formula I, II, III, and IV, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of ALK2 kinase. Also provided are pharmaceutical compositions comprising a compound of formula I, II, III, or IV, or pharmaceutically acceptable salt thereof, and methods involving use of the compounds or pharmaceutically acceptable salts thereof and compositions in the treatment and prevention of various diseases and conditions, such as fibrodysplasia ossificans progressiva.
    Type: Grant
    Filed: February 13, 2023
    Date of Patent: August 6, 2024
    Assignee: BioCryst Pharmaceuticals, Inc.
    Inventors: Pravin L. Kotian, Yarlagadda S. Babu, V. Satish Kumar, Weihe Zhang, Peng-Cheng Lu, Krishnan Raman
  • Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors
    Patent number: 12043610
    Abstract: Disclosed are compounds of formulae I and II, and pharmaceutically acceptable salts and prodrugs thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.
    Type: Grant
    Filed: April 27, 2022
    Date of Patent: July 23, 2024
    Assignee: BioCryst Pharmaceuticals, Inc.
    Inventors: Pravin L. Kotian, Yarlagadda S. Babu, Weihe Zhang, Peng-Cheng Lu, Minwan Wu, Wei Lv, Trung Xuan Nguyen, Zhao Dang, Venkat R. Chintareddy, V. Satish Kumar, Krishnan Raman
  • BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5
    Publication number: 20240239752
    Abstract: Disclosed are compounds of formulae (I)-(IV), and pharmaceutically acceptable salts thereof, which are inhibitors of kallikrein-related peptidase 5 (KLK5). Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant KLK5 activity, such as Netherton Syndrome.
    Type: Application
    Filed: April 14, 2022
    Publication date: July 18, 2024
    Inventors: Pravin L. Kotian, Yarlagadda S. Babu, Weihe Zhang, Peng-Cheng Lu, Zhao Dang, Krishnan Raman
  • Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors
    Patent number: 11866418
    Abstract: Disclosed are compounds of formulae I and II, and pharmaceutically acceptable salts and prodrugs thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.
    Type: Grant
    Filed: April 27, 2022
    Date of Patent: January 9, 2024
    Assignee: BioCryst Pharmaceuticals, Inc.
    Inventors: Pravin L. Kotian, Yarlagadda S. Babu, Weihe Zhang, Peng-Cheng Lu, Minwan Wu, Wei Lv, Trung Xuan Nguyen, Zhao Dang, Venkat R. Chintareddy, V. Satish Kumar, Krishnan Raman
  • IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE
    Publication number: 20230271975
    Abstract: Disclosed are compounds of formula I, II, III, and IV, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of ALK2 kinase. Also provided are pharmaceutical compositions comprising a compound of formula I, II, III, or IV, or pharmaceutically acceptable salt thereof, and methods involving use of the compounds or pharmaceutically acceptable salts thereof and compositions in the treatment and prevention of various diseases and conditions, such as fibrodysplasia ossificans progressiva.
    Type: Application
    Filed: February 13, 2023
    Publication date: August 31, 2023
    Inventors: PRAVIN L. Kotian, Yarlagadda S. Babu, V. Satish Kumar, Weihe Zhang, Peng-Cheng Lu, Krishnan Raman
  • Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors
    Patent number: 11708347
    Abstract: Disclosed are compounds of formulae I and II, and pharmaceutically acceptable salts and prodrugs thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.
    Type: Grant
    Filed: February 5, 2021
    Date of Patent: July 25, 2023
    Assignee: BioCryst Pharmaceuticals, Inc.
    Inventors: Pravin L. Kotian, Yarlagadda S. Babu, Weihe Zhang, Peng-Cheng Lu, Minwan Wu, Wei Lv, Trung Xuan Nguyen, Zhao Dang, Venkat R. Chintareddy, V. Satish Kumar, Krishnan Raman
  • BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF
    Publication number: 20230218578
    Abstract: Disclosed are compounds of formula I, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising a compound of formula I, and methods involving use of the compounds and compositions in the treatment and prevention of diseases and conditions characterized by aberrant complement system activity.
    Type: Application
    Filed: January 23, 2023
    Publication date: July 13, 2023
    Inventors: Pravin L. Kotian, Yarlagadda S. Babu, Weihe Zhang, Lakshminarayana Vogeti, Minwan Wu, Venkat R. Chintareddy, Krishnan Raman
  • Imidazole-containing inhibitors of ALK2 kinase
    Patent number: 11661426
    Abstract: Disclosed are compounds of formula I, II, III, and IV, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of ALK2 kinase. Also provided are pharmaceutical compositions comprising a compound of formula I, II, III, or IV, or pharmaceutically acceptable salt thereof, and methods involving use of the compounds or pharmaceutically acceptable salts thereof and compositions in the treatment and prevention of various diseases and conditions, such as fibrodysplasia ossificans progressiva.
    Type: Grant
    Filed: June 14, 2018
    Date of Patent: May 30, 2023
    Assignee: BioCryst Pharmaceuticals, Inc.
    Inventors: Pravin L. Kotian, Yarlagadda S. Babu, V. Satish Kumar, Weihe Zhang, Peng-Cheng Lu, Krishnan Raman
  • PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS
    Publication number: 20230159536
    Abstract: Disclosed are compounds of formula (I), and pharmaceutically acceptable salts thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.
    Type: Application
    Filed: April 2, 2021
    Publication date: May 25, 2023
    Inventors: Pravin L. Kotian, Yarlagadda S. Babu, Minwan Wu, Zhao Dang, Trung Xuan Nguyen, Krishnan Raman
  • SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS
    Publication number: 20230099716
    Abstract: Disclosed are compounds of formulae I and II, and pharmaceutically acceptable salts and prodrugs thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.
    Type: Application
    Filed: April 27, 2022
    Publication date: March 30, 2023
    Inventors: Pravin L. Kotian, Yarlagadda S. Babu, Weihe Zhang, Peng-Cheng Lu, Minwan Wu, Wei Lv, Trung Xuan Nguyen, Zhao Dang, Venkat R. Chintareddy, V. Satish Kumar, Krishnan Raman